|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6414a was selected from the N-term region of human Drosophila Parkin. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Parkin is thought to play a role in the ubiquitin/proteasome pathway for protein degradation. The amino terminus bears sequence homology to ubiquitin while functionally it acts as a RING-type ubiquitin protein ligase (E3) that coordinates the transfer of ubiquitin to substrate proteins, thus targeting them for degradation by the proteasome. Mutations in the human version of the protein are known to cause autosomal recessive juvenile parkinsonism.
Zhong,L. et al. J. Biol. Chem. 280 (10), 9425-9430 (2005)Pesah,Y. et al. Development 131 (9), 2183-2194 (2004)Haywood,A.F. et al. BMC Neurosci 5, 14 (2004)Finney,N. et al. J. Biol. Chem. 278 (18), 16054-16058 (2003)Yang,Y. et al. Neuron 37 (6), 911-924 (2003)
If you have any additional inquiries please email technical services at email@example.com.